ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 242 filers reported holding ACCELERON PHARMA INC in Q3 2020. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $13,576,000 | +0.3% | 78,882 | -26.8% | 0.01% | 0.0% |
| Q2 2021 | $13,531,000 | -2.5% | 107,823 | +5.4% | 0.01% | -10.0% |
| Q1 2021 | $13,877,000 | -3.1% | 102,329 | -8.6% | 0.01% | -9.1% |
| Q4 2020 | $14,327,000 | +8.0% | 111,979 | -5.0% | 0.01% | -8.3% |
| Q3 2020 | $13,264,000 | +19.4% | 117,867 | +1.0% | 0.01% | +9.1% |
| Q2 2020 | $11,113,000 | -17.8% | 116,650 | -22.5% | 0.01% | -31.2% |
| Q1 2020 | $13,522,000 | +28.4% | 150,464 | -24.3% | 0.02% | +60.0% |
| Q4 2019 | $10,534,000 | +111.9% | 198,673 | +57.9% | 0.01% | +100.0% |
| Q3 2019 | $4,972,000 | +2.3% | 125,831 | +6.3% | 0.01% | 0.0% |
| Q2 2019 | $4,862,000 | +10.8% | 118,347 | +25.5% | 0.01% | +25.0% |
| Q1 2019 | $4,390,000 | -18.3% | 94,276 | -23.6% | 0.00% | -33.3% |
| Q4 2018 | $5,373,000 | -37.3% | 123,366 | -17.5% | 0.01% | -25.0% |
| Q3 2018 | $8,563,000 | +14.9% | 149,617 | -2.6% | 0.01% | 0.0% |
| Q2 2018 | $7,451,000 | +51.1% | 153,558 | +21.8% | 0.01% | +60.0% |
| Q1 2018 | $4,930,000 | -45.6% | 126,097 | -40.9% | 0.01% | -44.4% |
| Q4 2017 | $9,056,000 | +659.1% | 213,387 | +567.6% | 0.01% | +800.0% |
| Q3 2017 | $1,193,000 | +47.1% | 31,964 | +0.6% | 0.00% | 0.0% |
| Q4 2016 | $811,000 | -32.0% | 31,768 | -3.5% | 0.00% | 0.0% |
| Q3 2016 | $1,192,000 | +6.2% | 32,931 | -0.2% | 0.00% | 0.0% |
| Q2 2016 | $1,122,000 | +24.7% | 33,012 | -3.2% | 0.00% | 0.0% |
| Q1 2016 | $900,000 | -49.9% | 34,117 | -7.5% | 0.00% | -50.0% |
| Q4 2015 | $1,798,000 | +95.2% | 36,874 | -0.3% | 0.00% | +100.0% |
| Q3 2015 | $921,000 | +19.9% | 36,981 | +52.3% | 0.00% | 0.0% |
| Q2 2015 | $768,000 | +107.6% | 24,283 | +149.8% | 0.00% | – |
| Q1 2015 | $370,000 | -2.4% | 9,721 | 0.0% | 0.00% | – |
| Q4 2014 | $379,000 | +48.6% | 9,721 | +15.3% | 0.00% | – |
| Q3 2014 | $255,000 | – | 8,431 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |